US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

IMNN

Imunon (IMNN)

Imunon Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMNN

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMNN	Imunon Inc
2024/05/08	21 : 00	GlobeNewswire Inc.	IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO	NASDAQ:IMNN	Imunon Inc
2024/05/07	00 : 00	GlobeNewswire Inc.	IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024	NASDAQ:IMNN	Imunon Inc
2024/04/18	21 : 30	GlobeNewswire Inc.	IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101	NASDAQ:IMNN	Imunon Inc
2024/04/11	21 : 00	GlobeNewswire Inc.	IMUNON Reports Compliance with Nasdaq Listing Requirements	NASDAQ:IMNN	Imunon Inc
2024/03/28	21 : 00	GlobeNewswire Inc.	IMUNON Reports 2023 Financial Results and Provides Business Update	NASDAQ:IMNN	Imunon Inc
2024/03/25	21 : 30	GlobeNewswire Inc.	IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses	NASDAQ:IMNN	Imunon Inc
2024/03/22	06 : 00	GlobeNewswire Inc.	IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024	NASDAQ:IMNN	Imunon Inc
2024/03/13	21 : 00	GlobeNewswire Inc.	IMUNON Files IND Application to Begin Human Testing of IMNN-101	NASDAQ:IMNN	Imunon Inc
2024/03/13	06 : 00	GlobeNewswire Inc.	IMUNON Announces Leadership Change	NASDAQ:IMNN	Imunon Inc
2024/02/29	22 : 30	GlobeNewswire Inc.	Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5	NASDAQ:IMNN	Imunon Inc
2024/02/27	22 : 30	GlobeNewswire Inc.	Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	NASDAQ:IMNN	Imunon Inc
2024/02/22	22 : 00	GlobeNewswire Inc.	IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine	NASDAQ:IMNN	Imunon Inc
2024/02/10	06 : 09	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:IMNN	Imunon Inc
2023/12/30	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMNN	Imunon Inc
2023/12/21	07 : 15	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:IMNN	Imunon Inc
2023/12/12	06 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMNN	Imunon Inc
2023/12/12	06 : 05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IMNN	Imunon Inc
2023/12/11	22 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMNN	Imunon Inc
2023/12/11	22 : 30	GlobeNewswire Inc.	IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:IMNN	Imunon Inc
2023/11/14	23 : 00	GlobeNewswire Inc.	IMUNON’s VP of R&D to Present at the Vaccines Summit-2023	NASDAQ:IMNN	Imunon Inc
2023/11/14	22 : 00	GlobeNewswire Inc.	IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update	NASDAQ:IMNN	Imunon Inc
2023/11/07	22 : 30	GlobeNewswire Inc.	IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023	NASDAQ:IMNN	Imunon Inc
2023/10/23	21 : 30	GlobeNewswire Inc.	IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress	NASDAQ:IMNN	Imunon Inc
2023/10/19	21 : 30	GlobeNewswire Inc.	IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations	NASDAQ:IMNN	Imunon Inc
2023/10/18	21 : 30	GlobeNewswire Inc.	IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer	NASDAQ:IMNN	Imunon Inc
2023/10/06	21 : 30	GlobeNewswire Inc.	IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board	NASDAQ:IMNN	Imunon Inc
2023/09/28	21 : 30	GlobeNewswire Inc.	IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer	NASDAQ:IMNN	Imunon Inc
2023/09/26	21 : 30	GlobeNewswire Inc.	IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies	NASDAQ:IMNN	Imunon Inc
2023/09/13	21 : 30	GlobeNewswire Inc.	IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET	NASDAQ:IMNN	Imunon Inc

Showing the most relevant articles for your search:NASDAQ:IMNN

1 2 3 次へ >>

Financial Select Sector

US Dollar vs Sterling

Energy Select Sector SPDR

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約